阿立哌唑治疗47例首发精神分裂症的临床分析

Clinical Analysis of Aripiprazole in Treating 47 cases of First Schizopenia

目的了解阿立哌唑对首发精神分裂症的临床疗效和不良反应。方法对门诊和住院的47例精神分裂症患者给予阿立哌唑治疗,疗程12周,以阳性和阴性症状量表(PANSS)评定疗效,以副反应量表(TESS)评定不良反应。结果阿立哌唑对首发精神分裂症有肯定疗效,剂量在10～30 mg/d。PANSS总分和各量表分,在自疗2周后显著下降,常见不良反应为疲劳、头胀,但多较轻,患者能耐受,1周后缓解[1]。结论阿立哌唑,是一种安全、有效的新型抗精神病药。

Objective To understand the clinical efficacy and adverse reactions of aripiprazole in treating first schizophrenia.Methods 47 cases of out-patient and hospitalization patients with schizophrenia were adopted aripiprazole therapy,a course of treatment is 12 weeks,To assess efficacy by positive and negative symptom scale（PANSS） and assess adverse reactions by Emergent Symptom Scale（TESS） assessment.Results of Aripiprazole has certain effects for the first-episode schizophrenia,dose of 10 - 30 mg / d,PANSS total score and each sub-scale self-treatment significantly decreased after 2 weeks.The common reactions is not trace of fatigue,stretching,but Multi-light,the patient can tolerate,1 week after mitigation.Conclusion Aripiprazole might be a safe and effective new antipsychotics.